Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Eluvia Is A 'Step Ahead' Of - Not Catching Up To - Rival Peripheral DES, Says BSX

This article was originally published in Clinica

Executive Summary

Peripheral interventions may not be Boston Scientific’s biggest division, but it boasted the highest sales growth among all the other business units in the company’s latest quarterly results. The recent additions to the expanding peripheral interventions portfolio will help maintain this upward trajectory, according to Jane Healy, the recently appointed vice-president of Boston Scientific’s European peripheral interventions unit.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst